Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Lifted by Cetera Investment Advisers

Key Points

• Cetera Investment Advisers increased its stake in Alnylam Pharmaceuticals by 68.1% in the first quarter, holding shares worth approximately $2.165 million now.
• CEO Yvonne Greenstreet sold 19,297 shares, representing a 28.28% decrease in her position, for a total transaction value of about $5.9 million.
• Alnylam Pharmaceuticals experienced a share price increase of 0.9%, closing at $438.93, following a strong quarterly earnings report that exceeded analysts' expectations.

Cetera Investment Advisers raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 68.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 8,017 shares of the biopharmaceutical company's stock after acquiring an additional 3,247 shares during the period. Cetera Investment Advisers' holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Capital World Investors raised its holdings in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the period. Northern Trust Corp grew its stake in shares of Alnylam Pharmaceuticals by 19.6% during the 4th quarter. Northern Trust Corp now owns 878,860 shares of the biopharmaceutical company's stock valued at $206,805,000 after buying an additional 143,941 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 60.9% during the 4th quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company's stock valued at $191,391,000 after buying an additional 307,702 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,899,281.72. This represents a 39.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $3.04 on Tuesday, hitting $431.97. 247,382 shares of the company's stock were exchanged, compared to its average volume of 934,724. The firm has a market cap of $56.62 billion, a PE ratio of -174.79 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $445.20. The stock has a fifty day moving average of $334.37 and a two-hundred day moving average of $285.99. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773,689 billion for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.13) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ALNY. Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Jefferies Financial Group upped their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Finally, BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 24th. Four equities research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $403.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.